Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
4,803 total articles
Arthur J. Gallagher & Co. (AJG) just traded back toward the low end of its 52-week range after a pullback. The business generates $1.785B in free cash flow, carries modest leverage and still yields a small dividend. For patient, risk-aware traders there's an asymmetric opportunity: buy near $214, target $260 over the next 45 trading days and use a …
Global Ship Lease (GSL) is exposed to a near-term rerating catalyst: a material portion of its fleet rolls off legacy charters into a market with firmer spot/time charter rates. Combine that with recurring trade-route disruptions and tightening vessel supply, and GSL offers an asymmetric upside versus downside if you buy on weakness. This trade pla…
Marvell (MRVL) is squarely in the AI infrastructure story after a $2B strategic investment and an increasingly visible optical and custom-silicon ramp. Fundamentals justify participation, but the stock is expensive and technically overbought. This trade targets a mid-term (~45 trading days) run to $160 with a disciplined stop at $118.
Coeur Mining (CDE) looks mispriced relative to its post-acquisition cash generation profile. The New Gold deal, aggressive $750M repurchase, and new dividend should lift per-share metrics and reduce public float while the company still shows conservative balance sheet metrics. This trade targets a mid-term re-rating toward the January highs, with a…
Bath & Body Works (BBWI) looks cheap on multiple metrics, generates strong free cash flow and pays a healthy yield, but a recent string of missed guidance and active securities litigation create near-term volatility. This trade idea lays out an entry at $18.10 with a stop at $16.50 and a primary target of $24.00 on a 46-180 trading day time frame.
Tyson Foods is reshaping its earnings profile as record beef prices and operational discipline push margins higher. The stock trades with a modest EV/EBITDA of 11.7 and yields ~3%, offering a pragmatic entry for investors willing to give the company a multi-month runway for supply-side recovery and margin normalization.
Uber is cheap relative to its cash generation and growth optionality. With a market cap near $145B, trailing EPS of $4.94 and free cash flow of $9.09B, the setup favors a mid-term long that captures re-rating catalysts from AI infrastructure wins, robotaxi partnerships and persistent delivery demand. I outline an actionable entry at $70.50, a stop …
Gogo is a small-cap aviation connectivity provider that looks primed for a re-rating as military certifications (SDG) and EASA Supplemental Type Certificates for its Galileo HDX antenna drive new revenue channels. The shares trade at roughly $4.58 with a $616M market cap and attractive EV/EBITDA; we upgrade to Buy and lay out an actionable mid-term…
W.W. Grainger proved me wrong by outperforming expectations on durability and margin recovery. The stock sits near its 52-week high but the underlying business — high-margin, recurring MRO and a fast-growing e-commerce channel — supports a measured long trade. This idea lays out entry, stop and target, the fundamental case, catalysts and the key ri…
QuantumScape's stock has retraced sharply from its 52-week highs, but the company is entering a make-or-break stretch of field tests and pilot production ramp milestones in 2026. With a market cap near $3.9B, low debt and a stretched valuation profile, this is a tactical long idea: defined entry at $6.30, stop at $5.50, target at $9.00, horizon 45 …
Albemarle (ALB) is being upgraded to a Buy. The company is executing cost cuts and asset sales, generating positive free cash flow, and stands to gain from U.S. policy on critical minerals and recovering lithium prices. With a market cap near $20.5B, an improving operational profile, and a reasonable valuation on cash-flow metrics, ALB offers a tra…
Amazon is rightly positioned as a leader in cloud services, but its role in the AI hardware stack is fundamentally different from Broadcom's. Investors bidding Amazon up on AI dominance are implicitly pricing in operating leverage and margin expansion that belong more to custom silicon suppliers. For mid-term traders, a disciplined short against ov…
IAMGOLD's 2025 production beat and 2026 guidance, combined with a modest leverage profile and a market cap of about $11.8B, create a tradeable long setup around $20. We favor buying into momentum with strict risk controls: entry $20.00, stop $16.50, target $27.50 for a mid-term swing.
CoStar looks like a compounding machine on paper but the market is pricing a mismatch between growth talk and cash reality. With EPS near zero, free cash flow of only $41M, and an EV/EBITDA north of 76x, I'm laying out a mid-term short: entry $36.50, initial target $28.00, stop $40.50. This trade bets that lofty 2026 expectations and a $1.5B buybac…
Ondas is executing a rapid pivot into defense, counter-drone and high-altitude ISR after a blowout Q4 that set FY2026 guidance to at least $375M. The upside is real — World Cup security wins, a World View acquisition, and ~$1.5B in cash create optionality — but margins, integration risk, and a stretched valuation demand caution. This is a cautious …
Riley Exploration Permian (REPX) offers a compelling risk/reward today: high free cash flow, a sub-1x leverage profile, and a dividend that yields roughly 4% at recent prices. The stock trades near its 52-week high and shows stretched technicals, so execution matters. This trade lays out an entry, stop and target for a long position over a 180 trad…
Snowflake plunged to a 52-week low after a volatile session, but fundamentals and cloud economics leave room for a meaningful rebound as the company rolls AI and agentic features into Data Cloud. This trade idea lays out a precise long entry, stop, and target with catalysts and risks clearly framed.
Oracle’s share price has been punished this year despite strong cloud growth, a record backlog and accelerating profitability. The market is pricing an execution catastrophe into the stock — a scenario that looks unlikely given recent results, product wins and an improving margin profile. This trade idea proposes a disciplined long with a $135 entr…
ASML's shares have pulled back amid macro worries, yet the company's unique position in extreme ultraviolet (EUV) lithography, a €38.8B backlog and fresh large orders keep the structural growth story intact. This trade idea lays out a mid-term (45 trading days) buy with strict risk controls: entry $1480.21, stop $1350.00, target $1600.00.
ICU Medical (ICUI) looks set to convert recent profitability beats and steady free cash flow into cleaner margin leverage and the ability to return capital. On a market cap near $3.1B and EV/EBITDA ~13.3, the setup supports a tactical long over the next 45 trading days. Entry, stop and target are concrete and keyed to both fundamental catalysts and…
Rithm Capital (RITM) trades like a dividend-first REIT with optional upside. At roughly $9.94 today, the company yields about 10% and carries a mixed fundamental picture - heavy leverage and negative free cash flow, but tangible earning power and an asset base tied to mortgage servicing rights and non-agency MBS. This trade aims to capture income w…
We upgrade Texas Pacific Land (TPL) to long on the thesis that Permian landowners with scale and optionality will capture outsized value as data centers, power, and grid infrastructure migrate closer to energy supply. Entry at $405.42, target $540.00, stop $360.00; horizon: long term (180 trading days).
<p>Software multiples are being indiscriminately repriced. Claude Mythos is an enterprise-focused AI software provider with recurring revenue and margin leverage. Recent sector de-rating has pushed the stock into a tactical buy range. This trade idea lays out entry, stop, targets, catalysts and risks with a mid-term horizon while leaving room for a…
Veeva's specialized life-sciences cloud, recurring-contract economics, and strong cash generation make it a poor candidate for wholesale displacement by generic AI platforms. The stock is oversold (RSI ~22), near its 52-week low of $148.05, and management recently authorized a $2B buyback. We upgrade to a buy on the dip with a clear entry, stop and…
Forte Biosciences (FBRX) has ripped from its $4.90 52-week low to trade near $34 after a string of bullish technicals and renewed clinical interest in its live biotherapeutic FB-401. With a tight float (~12.1M shares), $471M market cap and positive momentum indicators, there is a tradable setup ahead of near-term data readouts — but the company's n…
